Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2024-05-17 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2023 Annual General Meeting Resolution Announcement" from Jiangsu Haoubo Biopharmaceutical Co., Ltd. It details the date and location of the AGM, attendance, voting results on various proposals including the 2023 Annual Report, Board and Supervisory reports, financial statements, profit distribution, and other corporate matters. The document primarily reports the voting results and resolutions passed at the AGM. It does not contain the full annual report or detailed financial statements but rather the official announcement of the voting outcomes and resolutions from the AGM. The document length is 4373 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of "Declaration of Voting Results & Voting Rights Announcements" (DVA).
2024-05-17 Chinese
国浩律师（上海）事务所关于江苏浩欧博生物医药股份有限公司2023 年年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2023 Annual General Meeting (AGM) of Jiangsu Haoubo Biopharmaceutical Co., Ltd. It discusses the legality of the AGM's convening, attendance, agenda, and voting procedures. The document does not contain financial statements or detailed financial performance data but focuses on the legal aspects of the AGM process. The document length is short (2017 characters) and is clearly a legal opinion related to the AGM, not the AGM materials or minutes themselves. Therefore, it fits best under the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions related to the meeting.
2024-05-17 Chinese
华泰联合证券有限责任公司关于江苏浩欧博生物医药股份有限公司2023年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2023年度持续督导跟踪报告" (2023 Annual Continuous Supervision Follow-up Report) issued by the sponsor institution 华泰联合证券有限责任公司 for 江苏浩欧博生物医药股份有限公司. It contains detailed information on company risks, financial performance, R&D progress, fundraising usage, and compliance with regulatory requirements. The content includes extensive financial data, operational risks, and detailed descriptions of business activities and financial indicators for the year 2023. The document is lengthy (15,000 characters) and contains substantive financial and operational data rather than just an announcement or certification. It is not a full annual report (10-K) but a continuous supervision follow-up report typically issued by a sponsor or underwriter to monitor a listed company's compliance and performance post-IPO. This type of document is best classified under Regulatory Filings (RNS) as it is a regulatory compliance and monitoring report that does not fit into other specific categories like Annual Report, Interim Report, or Audit Report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-05-14 Chinese
江苏浩欧博生物医药股份有限公司关于以集中竞价交易方式回购公司股份比例达到总股本1%暨回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase program, including details such as the number of shares repurchased, percentage of total share capital, price range, and total amount spent. It references regulatory rules about disclosure requirements for share repurchases and provides updates on the repurchase activity. The document does not contain financial statements or detailed financial analysis but is focused on the company's own shares transactions. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2024-05-14 Chinese
江苏浩欧博生物医药股份有限公司关于召开2023年度暨2024年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of an upcoming investor performance explanation meeting (业绩说明会) for the 2023 annual and 2024 first quarter results. It provides the meeting time, location, participation method, and contact information. It references that the 2023 annual report and 2024 first quarter report have already been published on April 26 and April 29, respectively, but this document itself is not the report or transcript. It is a notice about the investor presentation event where management will discuss and answer questions about the financial results. This fits the definition of an Investor Presentation (IP) announcement rather than the report itself or a call transcript. The document length is short (1551 characters), and it is clearly an announcement of a meeting for discussing financial results, not the results themselves or a transcript. Therefore, the correct classification is Investor Presentation (IP).
2024-05-14 Chinese
江苏浩欧博生物医药股份有限公司2023年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2023 年年度股东大会会议资料" which translates to "2023 Annual General Meeting (AGM) Meeting Materials". It contains detailed agenda items, meeting instructions, and multiple proposals to be discussed and voted on during the AGM. The content includes references to the company's 2023 Annual Report, Board of Directors' 2023 Annual Work Report, Supervisory Board's 2023 Annual Work Report, financial reports, profit distribution plans, and other governance and operational matters to be deliberated at the AGM. The document is clearly a set of materials prepared for the Annual General Meeting rather than the Annual Report itself or any other type of filing. It is comprehensive and lengthy (15,000 characters), consistent with AGM materials. Therefore, the appropriate classification is AGM Information (AGM-R).
2024-05-09 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.